Lucid Diagnostics Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request identifies 2023 Q4, this is an annual filing; the supplied text does not provide standalone fourth-quarter results. Dollar amounts below are in millions unless stated otherwise.
Business context
Lucid is a commercial-stage diagnostics company focused on detecting esophageal precancer and cancer. Its EsoGuard DNA test analyzes cells collected with the EsoCheck device. EsoCheck has FDA 510(k) clearance; EsoGuard was marketed as a laboratory-developed test (LDT), not an FDA-approved in-vitro diagnostic. Lucid is majority-owned by PAVmed.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $2.428 | $0.377 |
| Cost of revenue | $5.979 | $3.614 |
| Gross loss / gross margin | $(3.551) / approximately (146%) | $(3.237) / approximately (859%) |
| Operating expenses | $50.910 | $56.628 |
| Operating loss | $(48.482) | $(56.251) |
| Net loss | $(52.666) | $(56.171) |
| Net loss per share, basic and diluted | $(1.26) | $(1.55) |
| Cash used in operations | $(32.817) | $(29.685) |
Revenue increased by $2.051 million, primarily from testing performed at Lucid’s own laboratory. The company remained loss-making, with cost of revenue exceeding revenue. Operating expenses declined by $5.718 million, including lower general and administrative and research and development costs; lower stock-based compensation was a significant factor in the G&A decline. Net loss improved by $3.505 million. Results included a $2.980 million non-cash fair-value loss on the senior convertible note and $1.186 million in note issuance and offering costs.
At December 31, 2023, cash was $18.896 million, current assets $22.073 million and current liabilities $29.382 million, producing a working-capital deficit of approximately $7.3 million. Total liabilities were $29.581 million and stockholders’ equity was negative $2.311 million. The company reported no income tax expense or benefit, reflecting a full valuation allowance on deferred tax assets.
Debt, financing and subsequent events
- The March 2023 senior secured convertible note had $11.019 million face principal outstanding and a $13.950 million fair value at year-end. It bears 7.875% interest, matures March 21, 2025, is secured by company assets and includes installment repayments and financial covenants. Lucid reported compliance with the stated cash, market-capitalization and leverage tests at year-end.
- Cash from financing activities was $29.460 million in 2023, including $18.625 million from preferred stock and $10.000 million in net proceeds reported from the convertible note. Year-end cash decreased by $3.578 million.
- After year-end, on March 13, 2024, Lucid raised aggregate gross proceeds of approximately $18.16 million through Series B preferred stock transactions, including exchanges of outstanding Series A and A-1 preferred shares. Series B has a $1.2444 conversion price, voting rights, a liquidation preference and potential stock dividends.
- In January 2024, PAVmed elected to settle approximately $4.675 million of accrued fees and reimbursements by receiving 3,331,771 Lucid shares. In March 2024, the monthly PAVmed management fee was increased from $0.75 million to $0.83 million, effective January 1, 2024.
Material changes, outlook and risks
- Lucid launched EsoGuard 2.0 in November 2023, reporting improved assay performance and lower costs in validation studies. The filing describes additional clinical evidence as ongoing or expected in 2024, including publication of CLUE study results and data from PREVENT registries; these are forward-looking expectations, not reported outcomes.
- Management and the auditor stated that substantial doubt exists about Lucid’s ability to continue as a going concern. Lucid expects recurring losses and negative operating cash flow and says operations beyond March 2025 depend on substantial revenue growth, favorable reimbursement, direct employer contracting and additional financing or debt refinancing. The March 2024 preferred financing provides capital but does not remove this stated uncertainty.
- Medicare’s $1,938.01 payment determination for EsoGuard is not equivalent to coverage. The filing says Lucid had not obtained a final Medicare local coverage determination for the test; a May 2023 LCD set evidence criteria and stated no existing test had met them. Lucid planned to seek MolDX technical assessment. Most revenue to date came from out-of-network commercial insurance payments, whose collection and continuation are uncertain.
- FDA proposed phasing out general enforcement discretion for LDTs in October 2023. Lucid anticipated a final policy in 2024 and planned to pursue an FDA premarket pathway; the timing, requirements and commercial impact remained uncertain in the filing. EsoGuard and EsoCheck cannot be jointly marketed as a combined product without the required FDA approval.
- Additional principal risks include dependence on a single laboratory and on third-party manufacturing, limited revenue and customer adoption, reimbursement and billing uncertainty, dilution from preferred stock and convertible debt, and dependence on PAVmed for services and financing-related support. PAVmed’s control and related-party arrangements may create conflicts of interest.
- The company reported that management considered disclosure controls and internal control over financial reporting effective as of December 31, 2023. The auditor did not attest to internal-control effectiveness. No material pending legal proceeding was identified in the filing.
Important facts for investors to verify
- Current cash runway, near-term obligations and ability to meet the convertible note’s installments and covenants; the filing’s going-concern warning is material.
- Whether MolDX grants coverage after technical assessment, and whether commercial insurers provide durable coverage and collectible reimbursement.
- Actual testing volumes, collections, payer mix and unit economics, given revenue of $2.428 million against $5.979 million of cost of revenue.
- Regulatory developments for LDTs and the FDA pathway, including the evidence and costs required to maintain or expand commercialization.
- Potential dilution and voting effects from preferred-stock conversion and dividends, note repayments in shares, and PAVmed-related stock settlements and fees.